methylprednisolone and Infusion Site Adverse Event

methylprednisolone has been researched along with Infusion Site Adverse Event in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hauser, SL; Julian, L; Kappos, L; Köndgen, H; Li, C; Mayer, L; Napieralski, J; Racke, MK; Rammohan, K; Traboulsee, A; Wolinsky, JS; Zheng, H	1

Trials

1 trial(s) available for methylprednisolone and Infusion Site Adverse Event

Article	Year
Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple sclerosis and related disorders, 2019, Volume: 30 Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Histamine Antagonists; Humans; Immunologic Factors; Infusions, Intravenous; Injection Site Reaction; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis	2019

Article

Year

Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.

Multiple sclerosis and related disorders, 2019, Volume: 30

Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Histamine Antagonists; Humans; Immunologic Factors; Infusions, Intravenous; Injection Site Reaction; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis

2019